James C King1, John H Beigel2, Michael G Ison3, Richard E Rothman4, Timothy M Uyeki5, Robert E Walker1, James D Neaton6, John S Tegeris1, James A Zhou1, Kimberly L Armstrong1, Wendy Carter7, Peter S Miele7, Melissa S Willis1, Andrea F Dugas8, LaRee A Tracy7, David M Vock6, Rick A Bright1. 1. US Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Washington, District of Columbia. 2. National Institutes of Health, Division of Microbiology and Infectious Diseases, Bethesda, Maryland. 3. Divisions of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 4. Department of Emergency Medicine, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland; for the ED Influenza Research Consortium. 5. Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia. 6. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis. 7. US Food and Drug Administration, Division of Antiviral Products, Silver Spring, Maryland. 8. Shady Grove Medical Center, Rockville, Maryland.
Abstract
BACKGROUND: Since 1999, the US Food and Drug Administration approved neuraminidase and endonuclease inhibitors to treat uncomplicated outpatient influenza but not severe hospitalized influenza. After the 2009 pandemic, several influenza hospital-based clinical therapeutic trials were unsuccessful, possibly due to certain study factors. Therefore, in 2014, the US Health and Human Services agencies formed a Working Group (WG) to address related clinical challenges. METHODS: Starting in 2014, the WG obtained retrospective data from failed hospital-based influenza therapeutic trials and nontherapeutic hospital-based influenza studies. These data allowed the WG to identify factors that might improve hospital-based therapeutic trials. These included primary clinical endpoints, increased clinical site enrollment, and appropriate baseline enrollment criteria. RESULTS: During 2018, the WG received retrospective data from a National Institutes of Health hospital-based influenza therapeutic trial that demonstrated time to resolution of respiratory status, which was not a satisfactory primary endpoint. The WG statisticians examined these data and believed that ordinal outcomes might be a more powerful primary endpoint. Johns Hopkins' researchers provided WG data from an emergency-department (ED) triage study to identify patients with confirmed influenza using molecular testing. During the 2013-2014 influenza season, 4 EDs identified 1074 influenza-patients, which suggested that triage testing should increase enrollment by hospital-based clinical trial sites. In 2017, the WG received data from Northwestern Memorial Hospital researchers regarding 703 influenza inpatients over 5 seasons. The WG applied National Early Warning Score (NEWS) at patient baseline to identify appropriate criteria to enroll patients into hospital-based therapeutic trials. CONCLUSIONS: Data received by the WG indicated that hospital-based influenza therapeutic trials could use ordinal outcome analyses, ED triage to identify influenza patients, and NEWS for enrollment criteria.
BACKGROUND: Since 1999, the US Food and Drug Administration approved neuraminidase and endonuclease inhibitors to treat uncomplicated outpatient influenza but not severe hospitalized influenza. After the 2009 pandemic, several influenza hospital-based clinical therapeutic trials were unsuccessful, possibly due to certain study factors. Therefore, in 2014, the US Health and Human Services agencies formed a Working Group (WG) to address related clinical challenges. METHODS: Starting in 2014, the WG obtained retrospective data from failed hospital-based influenza therapeutic trials and nontherapeutic hospital-based influenza studies. These data allowed the WG to identify factors that might improve hospital-based therapeutic trials. These included primary clinical endpoints, increased clinical site enrollment, and appropriate baseline enrollment criteria. RESULTS: During 2018, the WG received retrospective data from a National Institutes of Health hospital-based influenza therapeutic trial that demonstrated time to resolution of respiratory status, which was not a satisfactory primary endpoint. The WG statisticians examined these data and believed that ordinal outcomes might be a more powerful primary endpoint. Johns Hopkins' researchers provided WG data from an emergency-department (ED) triage study to identify patients with confirmed influenza using molecular testing. During the 2013-2014 influenza season, 4 EDs identified 1074 influenza-patients, which suggested that triage testing should increase enrollment by hospital-based clinical trial sites. In 2017, the WG received data from Northwestern Memorial Hospital researchers regarding 703 influenza inpatients over 5 seasons. The WG applied National Early Warning Score (NEWS) at patient baseline to identify appropriate criteria to enroll patients into hospital-based therapeutic trials. CONCLUSIONS: Data received by the WG indicated that hospital-based influenza therapeutic trials could use ordinal outcome analyses, ED triage to identify influenza patients, and NEWS for enrollment criteria.
Authors: Francisco M Marty; Joan Vidal-Puigserver; Carol Clark; Sandeep K Gupta; Esperanza Merino; Denis Garot; Marianne J Chapman; Frédérique Jacobs; Eduardo Rodriguez-Noriega; Petr Husa; Denise Shortino; Helen A Watson; Phillip J Yates; Amanda F Peppercorn Journal: Lancet Respir Med Date: 2017-01-14 Impact factor: 30.700
Authors: Menno D de Jong; Michael G Ison; Arnold S Monto; Hristo Metev; Carol Clark; Brian O'Neil; Jenna Elder; Amy McCullough; Phil Collis; William P Sheridan Journal: Clin Infect Dis Date: 2014-08-12 Impact factor: 9.079
Authors: A Danielle Iuliano; Katherine M Roguski; Howard H Chang; David J Muscatello; Rakhee Palekar; Stefano Tempia; Cheryl Cohen; Jon Michael Gran; Dena Schanzer; Benjamin J Cowling; Peng Wu; Jan Kyncl; Li Wei Ang; Minah Park; Monika Redlberger-Fritz; Hongjie Yu; Laura Espenhain; Anand Krishnan; Gideon Emukule; Liselotte van Asten; Susana Pereira da Silva; Suchunya Aungkulanon; Udo Buchholz; Marc-Alain Widdowson; Joseph S Bresee Journal: Lancet Date: 2017-12-14 Impact factor: 79.321
Authors: Ross L Peterson; David M Vock; John H Powers; Sean Emery; Eduardo Fernandez Cruz; Sally Hunsberger; Mamta K Jain; Sarah Pett; James D Neaton Journal: Clin Trials Date: 2017-03-06 Impact factor: 2.486
Authors: John H Beigel; Pablo Tebas; Marie-Carmelle Elie-Turenne; Ednan Bajwa; Todd E Bell; Charles B Cairns; Shmuel Shoham; Jaime G Deville; Eric Feucht; Judith Feinberg; Thomas Luke; Kanakatte Raviprakash; Janine Danko; Dorothy O'Neil; Julia A Metcalf; Karen King; Timothy H Burgess; Evgenia Aga; H Clifford Lane; Michael D Hughes; Richard T Davey Journal: Lancet Respir Med Date: 2017-05-15 Impact factor: 30.700
Authors: Denise Andrews; Yumela Chetty; Ben S Cooper; Manjinder Virk; Stephen K Glass; Andrew Letters; Philip A Kelly; Malur Sudhanva; Dakshika Jeyaratnam Journal: BMC Infect Dis Date: 2017-10-10 Impact factor: 3.090
Authors: Katherine Adams; Mark W Tenforde; Shreya Chodisetty; Benjamin Lee; Eric J Chow; Wesley H Self; Manish M Patel Journal: Hum Vaccin Immunother Date: 2021-11-10 Impact factor: 3.452
Authors: Ross L Peterson; David M Vock; Abdel Babiker; John H Powers; Sally Hunsberger; Brian Angus; Armando Paez; James D Neaton Journal: Contemp Clin Trials Commun Date: 2019-06-21
Authors: John H Beigel; Kay M Tomashek; Lori E Dodd; Aneesh K Mehta; Barry S Zingman; Andre C Kalil; Elizabeth Hohmann; Helen Y Chu; Annie Luetkemeyer; Susan Kline; Diego Lopez de Castilla; Robert W Finberg; Kerry Dierberg; Victor Tapson; Lanny Hsieh; Thomas F Patterson; Roger Paredes; Daniel A Sweeney; William R Short; Giota Touloumi; David Chien Lye; Norio Ohmagari; Myoung-Don Oh; Guillermo M Ruiz-Palacios; Thomas Benfield; Gerd Fätkenheuer; Mark G Kortepeter; Robert L Atmar; C Buddy Creech; Jens Lundgren; Abdel G Babiker; Sarah Pett; James D Neaton; Timothy H Burgess; Tyler Bonnett; Michelle Green; Mat Makowski; Anu Osinusi; Seema Nayak; H Clifford Lane Journal: N Engl J Med Date: 2020-10-08 Impact factor: 91.245
Authors: Eric J Chow; Mark W Tenforde; Melissa A Rolfes; Benjamin Lee; Shreya Chodisetty; Julio A Ramirez; Alicia M Fry; Manish M Patel Journal: PLoS One Date: 2021-10-21 Impact factor: 3.240
Authors: Jeremy J Lim; Anna C Nilsson; Michael Silverman; Nimer Assy; Priya Kulkarni; Jacqueline M McBride; Rong Deng; Chloe Li; Xiaoying Yang; Allen Nguyen; Priscilla Horn; Mauricio Maia; Aide Castro; Melicent C Peck; Joshua Galanter; Tom Chu; Elizabeth M Newton; Jorge A Tavel Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Candace C Fuller; Austin Cosgrove; Kenneth Sands; Karla M Miller; Russell E Poland; Edward Rosen; Alfred Sorbello; Henry Francis; Robert Orr; Sarah K Dutcher; Gregory T Measer; Noelle M Cocoros Journal: Influenza Other Respir Viruses Date: 2021-10-25 Impact factor: 4.380